PMGC (ELAB) Competitors $6.18 -0.54 (-8.04%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$6.28 +0.10 (+1.62%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ELAB vs. SLXN, MBIO, COCP, ACXP, HOOK, PHXM, IMCC, BFRI, EVAX, and INABShould you be buying PMGC stock or one of its competitors? The main competitors of PMGC include Silexion Therapeutics (SLXN), Mustang Bio (MBIO), Cocrystal Pharma (COCP), Acurx Pharmaceuticals (ACXP), HOOKIPA Pharma (HOOK), PHAXIAM Therapeutics (PHXM), IM Cannabis (IMCC), Biofrontera (BFRI), Evaxion A/S (EVAX), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry. PMGC vs. Its Competitors Silexion Therapeutics Mustang Bio Cocrystal Pharma Acurx Pharmaceuticals HOOKIPA Pharma PHAXIAM Therapeutics IM Cannabis Biofrontera Evaxion A/S IN8bio Silexion Therapeutics (NASDAQ:SLXN) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Do institutionals and insiders have more ownership in SLXN or ELAB? 11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 22.2% of PMGC shares are held by institutional investors. 6.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 0.2% of PMGC shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings and valuation, SLXN or ELAB? PMGC has higher revenue and earnings than Silexion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A-$16.44MN/AN/APMGC$1.71M1.52-$6.25M-$433.87-0.01 Is SLXN or ELAB more profitable? Silexion Therapeutics' return on equity of 0.00% beat PMGC's return on equity.Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -355.74% PMGC N/A -62.73%-52.83% Do analysts recommend SLXN or ELAB? Silexion Therapeutics presently has a consensus target price of $75.00, indicating a potential upside of 2,152.25%. Given Silexion Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Silexion Therapeutics is more favorable than PMGC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk and volatility, SLXN or ELAB? Silexion Therapeutics has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500. Comparatively, PMGC has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Does the media favor SLXN or ELAB? In the previous week, PMGC had 3 more articles in the media than Silexion Therapeutics. MarketBeat recorded 4 mentions for PMGC and 1 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 1.00 beat PMGC's score of 0.64 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silexion Therapeutics Positive PMGC Positive SummarySilexion Therapeutics and PMGC tied by winning 6 of the 12 factors compared between the two stocks. Get PMGC News Delivered to You Automatically Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELAB vs. The Competition Export to ExcelMetricPMGCDIVERSIFIED OPS IndustryMulti-Sector SectorNASDAQ ExchangeMarket Cap$2.85M$16.72B$15.29B$10.67BDividend YieldN/A3.50%3.35%4.86%P/E Ratio-0.0111.929.9127.13Price / Sales1.527.706.40126.20Price / CashN/A41.7739.3661.42Price / Book0.152.432.146.43Net Income-$6.25M$953.24M$923.70M$276.63M7 Day Performance-20.57%-0.88%-0.47%-0.77%1 Month Performance16.82%-5.60%-4.95%0.68%1 Year Performance-98.75%8.55%6.40%32.03% PMGC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELABPMGC0.7153 of 5 stars$6.18-8.0%N/A-98.8%$2.85M$1.71M-0.0118Gap DownSLXNSilexion Therapeutics3.2525 of 5 stars$3.54-2.7%$75.00+2,018.6%-94.5%$11.38MN/A0.00N/APositive NewsMBIOMustang Bio0.5841 of 5 stars$1.55-1.3%N/A-89.6%$11.37MN/A0.00100COCPCocrystal Pharma2.4163 of 5 stars$1.06-2.8%$6.00+466.0%-51.0%$11.20MN/A0.0010Positive NewsACXPAcurx Pharmaceuticals2.0146 of 5 stars$7.01+0.6%$31.00+342.2%-82.9%$11.05MN/A0.003Gap DownHOOKHOOKIPA Pharma2.2644 of 5 stars$0.87flat$4.50+417.2%-78.1%$10.60M$9.35M-0.15160PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049IMCCIM Cannabis0.0856 of 5 stars$1.96-1.5%N/A-11.8%$10.44M$39.44M0.00340Negative NewsGap DownBFRIBiofrontera1.7473 of 5 stars$1.00+0.7%$2.75+175.9%+6.0%$10.04M$37.32M0.0070News CoverageEVAXEvaxion A/S2.224 of 5 stars$6.53-7.9%$13.50+106.7%-58.5%$9.94M$3.34M0.0060Upcoming EarningsAnalyst ForecastINABIN8bio3.6225 of 5 stars$2.09-2.8%$92.00+4,301.9%-78.9%$9.76MN/A0.0020Positive News Related Companies and Tools Related Companies SLXN Alternatives MBIO Alternatives COCP Alternatives ACXP Alternatives HOOK Alternatives PHXM Alternatives IMCC Alternatives BFRI Alternatives EVAX Alternatives INAB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELAB) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMGC Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMGC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELAB Stock Alerts